Evidence map›Paper›PMID 34841369›Full record

ArticleThe Lancet. Microbe2021

Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study.

Marta Massanella, Rachel A Bender Ignacio, Javier R Lama, Amélie Pagliuzza, Sayan Dasgupta, Ricardo Alfaro, Jessica Rios, Carmela Ganoza, Delia Pinto-Santini, Trupti Gilada and 2 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in The Lancet. Microbe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02744040 (Modulating the Impact of Critical Events in Early HIV Infection), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02744040 nacompletednot on this map

Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use

TypeinterventionalSponsorFred Hutchinson Cancer CenterRan2017 to 2020Enrolled151ConditionsHIV InfectionArmsART initiation at time of HIV diagnosis, ART at 24 weeks
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Post-intervention control in HIV immunotherapy trials.Current opinion in HIV and AIDS · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Marta Massanella(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Rachel A Bender Ignacio(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Javier R Lama(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Amélie Pagliuzza(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Sayan Dasgupta(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Ricardo Alfaro(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Jessica Rios(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Carmela Ganoza(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Delia Pinto-Santini(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Trupti Gilada(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Ann Duerr(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Nicolas Chomont(M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).
Fred Hutch Cancer Center · USAsociación Civil Impacta Salud y Educación · PEUniversité de Montréal · CA

Funding

Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol UseR01DA040532 · NIDA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DUERR, ANN C · 2015 to 2019
$8.0M
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSMR01DA032106 · NIDA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DUERR, ANN C · 2011 to 2015
$6.6M
Determining the component causes of systemic immune activation that moderate HIV acquisition and establishment of the latent viral reservoirK23AI129659 · NIAID · UNIVERSITY OF WASHINGTON · PI BENDER IGNACIO, RACHEL ANN · 2017 to 2021
$868k
CIHR 364408NIAID NIH HHS K23 AI129659NIDA NIH HHS R01 DA032106NIDA NIH HHS R01 DA040532
6 · The paper itself

Abstract

backgroundEarly antiretroviral therapy (ART) initiation (ie, within 3 months of infection) limits establishment of the HIV reservoir. However, the effect of early ART initiation on the long-term dynamics of the pool of infected cells remains unclear.

methodsIn this longitudinal analysis, we included cisgender men who have sex with men (MSM) and transgender women (aged 18-54 years) at high risk for HIV infection, enrolled in the ongoing longitudinal MERLIN study in Peru between Oct 28, 2014, and Nov 8, 2018. Participants were eligible if they had been infected with HIV less than 90 days before enrolment, and if they had cryopreserved peripheral blood mononuclear cell (PBMC) samples. Participants were stratified into three groups on the basis of whether they initiated ART at 30 days or less (acute group), at 31-90 days (early group), or more than 24 weeks (deferred group) after the estimated date of detectable infection. PBMC samples were collected before ART initiation and longitudinally for up to 4 years on ART. The main outcomes were to establish the size of the HIV reservoir before ART initiation and to assess the effect of the timing of ART initiation on the decay of the HIV reservoir over 4 years follow-up. We quantified viral load, and isolated CD4 cells to quantify total HIV DNA, integrated HIV DNA and 2-long terminal repeat circles. Longitudinal analysis of active and inducible HIV reservoirs were measured by quantifying the frequency of CD4 cells producing multiply-spliced HIV RNA ex vivo and after in-vitro stimulation with a tat/rev induced limiting dilution assay (TILDA). A mixed-effects model from the time of ART initiation was used to measure longitudinal decays in viral loads and each HIV reservoir measure in each of the three groups.

findingsWe included 56 participants in this analysis, all of whom were MSM: 15 were in the acute group, 19 were in the early group, and 22 were in the deferred group. Participants in all three groups had similar levels of all HIV reservoir markers before ART initiation. All participants, including those in the acute group, had a pool of transcriptionally silent HIV-infected cells before ART initiation, as indicated by a substantial increase in TILDA measures upon stimulation. Longitudinal analysis over 4 years of ART revealed a biphasic decay of all HIV persistence markers, with a rapid initial decline followed by a slower decay in all participants. During the first-phase decay, the half-lives of both total and integrated HIV DNA and TILDA measures were significantly shorter in the acute group than in the early and deferred groups. During the second-phase decay, HIV reservoir markers continued to decline only in participants in the acute group.

interpretationParticipants who initiated ART within 30 days or less of HIV infection showed a steeper and more sustained decay in HIV reservoir measures, suggesting long-term benefit of acute ART initiation on reservoir clearance.

fundingThe US National Institutes of Health and the Canadian Institutes for Health Research.

Indexed as

HIV-1HIV InfectionsSexual and Gender MinoritiesAdolescentAdultAnti-Retroviral AgentsBiomarkersCanadaDNA, ViralFemaleHomosexuality, MaleHumansLeukocytes, MononuclearMaleMiddle AgedNeurofibromin 2Anti-Retroviral AgentsBiomarkersDNA, ViralNeurofibromin 2

Identifiers

PMID34841369
PMCPMC8622834
OpenAlexW3135967114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.